Prothrombin induced by vitamin K absence or antagonist‐II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C‐related cirrhosis treated with direct‐acting antiviral agents
暂无分享,去创建一个
A. de Silvestri | P. Lampertico | F. Ceriotti | R. D’Ambrosio | R. Perbellini | A. Sangiovanni | E. Degasperi | M. Iavarone | A. Rimondi | S. Uceda Renteria | M. Borghi | Mariangela Bruccoleri | A. Perego | C. Orsini | M. Bruccoleri
[1] J. Tojo,et al. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis , 2020, PloS one.
[2] C. Galli,et al. The combination of PIVKA‐II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long‐term oral therapy , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[3] P. Lampertico,et al. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. , 2020, Journal of hepatology.
[4] V. Paradis,et al. Biological response under treatment and prognostic value of protein induced by vitamin K absence or antagonist-II in a French cohort of patients with hepatocellular carcinoma , 2019, European journal of gastroenterology & hepatology.
[5] F. Ciardiello,et al. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study , 2019, Journal of Translational Medicine.
[6] P. Lampertico,et al. Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[7] Woochang Lee,et al. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early‐Stage Hepatocellular Carcinoma , 2019, Hepatology.
[8] P. Lampertico,et al. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct‐Acting Antivirals for HCV Infection , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] L. Bolondi,et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[10] M. Colombo,et al. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[11] W. Lau,et al. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis. , 2018, Hepatobiliary & pancreatic diseases international : HBPD INT.
[12] Albert Tran,et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. , 2018, Gastroenterology.
[13] M. Abecassis,et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.
[14] Giovanni Raimondo,et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. , 2018, Gastroenterology.
[15] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[16] S. Asch,et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.
[17] Guohong Deng,et al. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data , 2017, BMC Cancer.
[18] F. Izzo,et al. Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. , 2017, In vivo.
[19] M. Kudo,et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.
[20] Guohong Deng,et al. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients , 2016, Scientific Reports.
[21] L. Bolondi,et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.
[22] Peter J. Richardson,et al. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection , 2016, Hepatology.
[23] V. Paradis,et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. , 2015, Journal of hepatology.
[24] J. Lee,et al. Protein Induced by Vitamin K Antagonist-II (PIVKA-II) Is a Reliable Prognostic Factor in Small Hepatocellular Carcinoma , 2013, World Journal of Surgery.
[25] Dominik Heider,et al. A Combination of α-Fetoprotein and Des-γ-Carboxy Prothrombin Is Superior in Detection of Hepatocellular Carcinoma , 2013, Digestion.
[26] Yonggoo Kim,et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. , 2013, World journal of gastroenterology.
[27] M. Makuuchi,et al. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des‐γ‐carboxyprothrombin , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[28] H. Imamura,et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC , 2010, Journal of Gastroenterology.
[29] William M. Lee,et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. , 2010, Gastroenterology.
[30] J. Marrero,et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. , 2009, Gastroenterology.
[31] Dario Conte,et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease , 2007, Gut.
[32] Riccardo Lencioni,et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.
[33] M. Sherman,et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.